T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$1.3B |
| 2 |
American Airlines Group
AAL
|
+$853M |
| 3 |
Intuitive Surgical
ISRG
|
+$816M |
| 4 |
Morgan Stanley
MS
|
+$681M |
| 5 |
Wynn Resorts
WYNN
|
+$622M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$1.4B |
| 2 |
eBay
EBAY
|
+$763M |
| 3 |
DISCK
Discovery, Inc. Series C Common Stock
DISCK
|
+$760M |
| 4 |
Broadcom
AVGO
|
+$757M |
| 5 |
US Bancorp
USB
|
+$686M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.64% |
| 2 | Consumer Discretionary | 13.46% |
| 3 | Financials | 12.79% |
| 4 | Industrials | 12.13% |
| 5 | Technology | 9.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
326
Intel
INTC
$493B
| $320M | 0.07% |
10,354,740
-1,211,558
| -10% | -$33.2M |
|
327
Allegiant Air
ALGT
$2.42B
| $320M | 0.07% |
2,714,899
-11,258
| -0.4% | -$1.31M |
|
|
DYN
328
DELISTED
Dynegy, Inc.
DYN
| $316M | 0.07% |
9,091,780
+1,709,160
| +23% | +$52.8M |
|
329
Willis Towers Watson
WTW
$31.8B
| $315M | 0.07% |
2,746,850
-201,312
| -7% | -$22.6M |
|
330
McCormick & Company Non-Voting
MKC
$14.2B
| $313M | 0.07% |
8,755,176
-18,400
| -0.2% | -$657K |
|
331
HCA Healthcare
HCA
$89.1B
| $311M | 0.07% |
5,524,128
-794,306
| -13% | -$41.9M |
|
332
Verisk Analytics
VRSK
$23.6B
| $311M | 0.07% |
5,181,089
+224,272
| +5% | +$13.4M |
|
333
Essex Property Trust
ESS
$18.2B
| $311M | 0.07% |
1,680,161
+619,934
| +58% | +$110M |
|
334
Kilroy Realty
KRC
$4.24B
| $309M | 0.07% |
4,964,477
-760,812
| -13% | -$45.9M |
|
335
Federal Realty Investment Trust
FRT
$10.1B
| $309M | 0.07% |
2,552,341
+88,973
| +4% | +$10.5M |
|
336
Brunswick
BC
$5.28B
| $308M | 0.07% |
7,322,270
-77,195
| -1% | -$3.26M |
|
337
Halliburton
HAL
$28.2B
| $308M | 0.07% |
4,336,020
+1,402,759
| +48% | +$89.9M |
|
338
Landstar System
LSTR
$6.03B
| $307M | 0.07% |
4,797,940
+6,320
| +0.1% | +$396K |
|
339
Lennar Class A
LEN
$21.1B
| $307M | 0.07% |
7,681,405
-17,687
| -0.2% | -$670K |
|
|
KATE
340
DELISTED
Kate Spade & Company
KATE
| $307M | 0.07% |
8,040,913
-337,856
| -4% | -$12.1M |
|
|
CB
341
DELISTED
CHUBB CORPORATION
CB
| $304M | 0.07% |
3,300,556
+29,041
| +0.9% | +$2.67M |
|
|
XLNX
342
DELISTED
Xilinx Inc
XLNX
| $304M | 0.07% |
6,421,778
+43,599
| +0.7% | +$2.1M |
|
|
SIVB
343
DELISTED
SVB Financial Group
SIVB
| $304M | 0.07% |
2,603,143
-32,340
| -1% | -$3.61M |
|
|
TFCF
344
DELISTED
Twenty-First Century Fox, Inc. Class B
TFCF
| $300M | 0.06% |
8,770,540
-616,828
| -7% | -$20.4M |
|
|
345
Broadcom
AVGO
$1.98T
| $297M | 0.06% |
41,151,890
-112,772,900
| -73% | -$757M |
|
346
Global Payments
GPN
$22.7B
| $296M | 0.06% |
8,134,744
-32,400
| -0.4% | -$1.11M |
|
|
JNPR
347
DELISTED
Juniper Networks
JNPR
| $296M | 0.06% |
12,069,891
-23,347,735
| -66% | -$580M |
|
348
Equity Residential
EQR
$24.4B
| $295M | 0.06% |
4,689,513
-104,373
| -2% | -$6.34M |
|
349
C.H. Robinson
CHRW
$17B
| $294M | 0.06% |
4,609,361
+464,958
| +11% | +$27.3M |
|
350
Southern Copper
SCCO
$164B
| $294M | 0.06% |
10,565,431
+6,632,779
| +169% | +$180M |
|
Similar funds
T. Rowe Price Associates's Q2 2014 Portfolio in Review
As of Q2 2014, T. Rowe Price Associates held 2,596 positions worth $463B, up 3.9% from $445B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
T. Rowe Price Associates's Q2 2014 filing shows 97 new, 1,091 increased, 793 reduced and 67 closed positions. Its largest new stake was Teva Pharmaceuticals: 4,638,481 shares worth $243M. The largest sale was Procter & Gamble, an estimated $1.4B.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q2 2014 buy was Teva Pharmaceuticals: 4,638,481 shares worth $243M.
- T. Rowe Price Associates added most to Allergan Inc in Q2 2014, an estimated $1.3B increase.
- T. Rowe Price Associates's biggest Q2 2014 reduction was Procter & Gamble, cutting an estimated $1.4B.
- T. Rowe Price Associates fully exited Santander in Q2 2014, selling an estimated $134M.
- T. Rowe Price Associates's ten largest holdings make up 12% of its $463B portfolio in Q2 2014.
- T. Rowe Price Associates opened 97 new positions and closed 67 in Q2 2014.
- T. Rowe Price Associates's portfolio value rose 3.9% quarter-over-quarter to $463B.
Based on T. Rowe Price Associates's 13F filing for Q2 2014, filed 14 Aug 2014.